VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 333 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2016. The put-call ratio across all filers is 1.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $2,160,000 | +35.6% | 92,938 | +0.5% | 0.37% | +39.4% |
| Q1 2018 | $1,593,000 | -17.1% | 92,448 | 0.0% | 0.26% | -18.5% |
| Q4 2017 | $1,921,000 | +43.5% | 92,448 | -1.1% | 0.32% | +34.4% |
| Q3 2017 | $1,339,000 | -17.4% | 93,458 | -0.3% | 0.24% | -22.3% |
| Q2 2017 | $1,622,000 | +57.3% | 93,753 | +0.3% | 0.31% | +59.0% |
| Q1 2017 | $1,031,000 | -24.2% | 93,458 | -0.3% | 0.20% | -31.1% |
| Q4 2016 | $1,361,000 | -77.2% | 93,748 | -61.4% | 0.28% | -75.3% |
| Q3 2016 | $5,964,000 | +8.8% | 242,935 | -10.7% | 1.15% | +4.3% |
| Q2 2016 | $5,480,000 | -23.3% | 272,092 | +0.2% | 1.10% | -25.5% |
| Q1 2016 | $7,143,000 | -72.2% | 271,602 | +7.4% | 1.48% | -70.7% |
| Q4 2015 | $25,708,000 | -27.3% | 252,907 | +27.6% | 5.03% | -30.5% |
| Q3 2015 | $35,368,000 | – | 198,274 | – | 7.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |